HOP Civil

Strasbourg 67091

3 studies enrolling now · 19 studies all time

What they study most

Carcinoma, Non-Small-Cell Lung, Cardiovascular Diseases, Chronic Kidney Disease, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Extra-pulmonary Neuroendocrine Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Hypertension, Idiopathic Pulmonary Fibrosis, Interstitial Lung Diseases, Lung Cancer, Non-squamous, Non-small Cell, Lung Diseases, Interstitial

Studies at this site

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis — Recruiting now
• A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases — Recruiting now
• DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers — Recruiting now
• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease — Running, not enrolling
• DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy — Running, not enrolling
• Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment — Running, not enrolling
• A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer — Completed
• DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer — Running, not enrolling
• A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms — Completed
• A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) — Completed
• A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours — Completed
• A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) — Completed
• A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) — Completed
• Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment — Completed
• A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) — Completed
• Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) — Completed
• LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy — Completed
• Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3) — Completed